Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Corey J Langer

Showing results (211-220 of 225) with videos related to

Pageof 23
Sort By:
Cancer|January 31, 2024
Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab eraMichelle Iocolano, Nikhil Yegya-Raman, Cole Friedes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2017
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II TrialDong-Wan Kim, Marcello Tiseo, Myung-Ju Ahn, et al.
JCO Oncology Practice|July 3, 2024
Electronic Medical Record-Based Nudge Intervention to Increase Comprehensive Molecular Genotyping in Patients With Metastatic Non-Small Cell Lung Cancer: Results From a Prospective Clinical TrialMelina E Marmarelis, Dylan G Scholes, Tara L McWilliams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2016
Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with ChemotherapyDaniel H Sterman, Evan Alley, James P Stevenson, et al.
JTO Clinical and Research Reports|September 6, 2022
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory <i>ALK</i>+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) TrialsScott N Gettinger, Rudolf M Huber, Dong-Wan Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2020
Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung CancerCharu Aggarwal, Jeffrey C Thompson, Austin L Chien, et al.
JAMA Oncology|October 17, 2018
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung CancerCharu Aggarwal, Jeffrey C Thompson, Taylor A Black, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 16, 2023
Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidationNikhil Yegya-Raman, Sang Ho Lee, Cole Friedes, et al.
Clinical Lung Cancer|May 19, 2018
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and TechnologiesFred R Hirsch, Keith M Kerr, Paul A Bunn, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 2, 2008
Non-small cell lung cancerDavid S Ettinger, Wallace Akerley, Gerold Bepler, et al.
Pageof 23

Showing results (211-220 of 225) with videos related to

Sort By:
Pageof 23
Cancer|January 31, 2024
Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab eraMichelle Iocolano, Nikhil Yegya-Raman, Cole Friedes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2017
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II TrialDong-Wan Kim, Marcello Tiseo, Myung-Ju Ahn, et al.
JCO Oncology Practice|July 3, 2024
Electronic Medical Record-Based Nudge Intervention to Increase Comprehensive Molecular Genotyping in Patients With Metastatic Non-Small Cell Lung Cancer: Results From a Prospective Clinical TrialMelina E Marmarelis, Dylan G Scholes, Tara L McWilliams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2016
Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with ChemotherapyDaniel H Sterman, Evan Alley, James P Stevenson, et al.
JTO Clinical and Research Reports|September 6, 2022
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory <i>ALK</i>+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) TrialsScott N Gettinger, Rudolf M Huber, Dong-Wan Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2020
Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung CancerCharu Aggarwal, Jeffrey C Thompson, Austin L Chien, et al.
JAMA Oncology|October 17, 2018
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung CancerCharu Aggarwal, Jeffrey C Thompson, Taylor A Black, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 16, 2023
Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidationNikhil Yegya-Raman, Sang Ho Lee, Cole Friedes, et al.
Clinical Lung Cancer|May 19, 2018
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and TechnologiesFred R Hirsch, Keith M Kerr, Paul A Bunn, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 2, 2008
Non-small cell lung cancerDavid S Ettinger, Wallace Akerley, Gerold Bepler, et al.
Pageof 23